Other grades of this product :
| BAY-57-1293 Basic information |
| Product Name: | BAY-57-1293 | | Synonyms: | PRITELIVIR;AIC316;Benzeneacetamide, N-[5-(aminosulfonyl)-4-methyl-2-thiazolyl]-N-methyl-4-(2-pyridinyl)-;AIC316;N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide BAY57-1293 Pritelivir;2-METHYL-2-PROPANYL [4-(CHLOROSULFONYL)PHENYL]CARBAMATE;BAY571293(Pritelivir);BAY-57-1293;Pritelivir | | CAS: | 348086-71-5 | | MF: | C18H18N4O3S2 | | MW: | 402.49 | | EINECS: | | Product Categories: | Inhibitors | | Mol File: | 348086-71-5.mol |
| BAY-57-1293 Chemical Properties |
| Boiling point | 639.4±65.0 °C(Predicted) | | density | 1.396±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C(protect from light) | | solubility | insoluble in H2O; insoluble in EtOH; ≥13.9 mg/mL in DMSO | | form | solid | | pka | 9.31±0.60(Predicted) |
| BAY-57-1293 Usage And Synthesis |
| Uses | BAY 57-1293 is a potent inhibitor of herpes simplex virus (HSV) that target the virus helicase primase complex. | | Biological Activity | bay 57-1293 is a potent and safe inhibitor of hsv helicase-primase with ic50 value of 12nm [1].bay 57-1293 displays anti-herpes activity through inhibiting the helicase-primase and affecting the viral dna synthesis. in the in vitro viral replication assay, bay 57-1293 shows inhibition against hsv-1 f, hsv-2 g and acyclovir-resistant hsv-1 f mutant with ic50 value of 20nm. in the plaque reduction assay and the conventional cytopathogenicity assay, bay 57-1293 shows ic50 values of 0.01-0.02μm and 0.01-0.03μm, respectively. besides that, bay 57-1293 is active at an ic50 value of 10nm–30nm against all clinical isolates of hsv-1 and hsv-2. furthermore, bay 57-1293 is active in vivo. the oral administration of bay 57-1293 shows 10-fold more potent than valacyclovir in a murine model of disseminated herpes infection. in a rat lethal challenge model, bay 57-1293 exerts profound antiviral activity without toxic effects. [1, 2] | | references | [1] kleymann g, fischer r, betz u a k, et al. new helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. nature medicine, 2002, 8(4): 392-398.[2] betz u a k, fischer r, kleymann g, et al. potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor bay 57-1293. antimicrobial agents and chemotherapy, 2002, 46(6): 1766-1772. |
| BAY-57-1293 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye